Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™

Bibliography

• ARMITAGE JO: Treatment of non-Hodgkin's lymphoma. N Engl. J. Med. (1993) 328(14):1023–1030.
   PubMed Web of Science ®Google Scholar
• JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10–30.
   PubMed Web of Science ®Google Scholar
• ARMITAGE JO, WEISENBURGER DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol (1998) 16(8):2780–2795.
   Google Scholar
• MACMANUS MP, HOPPE RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol (1996) 14(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• REDDY S, SAXENA VS, PELLETTIERE EV, HENDRICKSON FR: Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16(3):687–692.
   PubMed Web of Science ®Google Scholar
• REISER M, DIEHL V: Current treatment of follicular non-Hodgkin's lymphoma. Eur. J. Cancer (2002) 38(9):1167–1172.
   PubMed Web of Science ®Google Scholar
• JOHNSON PW, ROHATINER AZ, WHELAN JS et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol (1995) 13(1):140–147.
   PubMed Web of Science ®Google Scholar
• HORNING SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol (1993) 20(5 Suppl. 5):75–88.
   Google Scholar
• ARDESHNA KM, SMITH P, NORTON A et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 362(9383):516–522.
   PubMed Web of Science ®Google Scholar
• LISTER TA, CULLEN MH, BEARD ME et al.: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br. Med. J. (1978) 1(6112):533–537.
   PubMed Web of Science ®Google Scholar
• KNOSPE WH, LOEB V JR, HUGULEY CM JR: Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer (1974) 33(2):555–562.
   PubMed Web of Science ®Google Scholar
• JONES SE, GROZEA PN, METZ EN et al.: Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer (1983) 51(6):1083–1090.
   Google Scholar
• KIMBY E, BJORKHOLM M, GAHRTON G et al.: Chlorambucil/ prednisone versus CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann. OncoL (1994) 5\(Suppl. 2):67–71.
   Google Scholar
• EZDINLI EZ, ANDERSON JR, MELVIN F, GLICK JH, DAVIS TE, O'CONNELL MJ: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. OncoL (1985) 3(0:769–775.
   PubMedGoogle Scholar
• MCLAUGHLIN P: Progress and promise in the treatment of indolent lymphomas. Oncologist (2002) 7(3):217–225.
   PubMed Web of Science ®Google Scholar
• WINTER JN, GASCOYNE RD, VAN BESIEN K: Low-grade lymphoma. Hematology: American Society of Hematology Educational Program Book (2004):203–220.
   Google Scholar
• ROHATINER AZ, GREGORY WM, PETERSON B et al.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. OncoL (2005) 23(10):2215–2223.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, TUCK M, ESTES J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N EngL J. Med. (2005) 352(5):441–449.
   PubMed Web of Science ®Google Scholar
• HORNING SJ: Follicular lymphoma: have we made any progress? Ann. OncoL (2000) 11 (Suppl. 0:23–27.
   Google Scholar
• SWENSON WT LYNCH CF, WOOLDRIDGE J, FORMAN-HOFFMAN VL, CHRISCHILLES E, LINK BK: Improved survival of follicular lymphoma patients in the surveillance, epidemiology, and end-results (SEER) program. J. Clin. OncoL (Meeting Abstracts) (2004) 22(14 Suppl.):Abstract #6578.
   Google Scholar
• HORNING SJ, ROSENBERG SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl. J. Med. (1984) 311(23):1471–1475.
   PubMed Web of Science ®Google Scholar
• KRIKORIAN JG, PORTLOCK CS, COONEY P, ROSENBERG SA: Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer (1980) 46(9):2093–2099.
   PubMed Web of Science ®Google Scholar
• DROBYSKI WR, QAZI R: Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am. J. Hematol. (1989) 31(2):138–141.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Biologic response modifiers: a report. NatL Cancer Inst. Monogr. (1983) 63:57–59.
   Google Scholar
• FEFER A: Interleukin-2: clinical applications-hematologic malignancies. In: Principles and Practice of the Biologic Therapy of Cancer (3rd ed.). Rosenberg SA (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2000):83–92.
   Google Scholar
• MILLER RA, MALONEY DG, WARNKE R, LEVY R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N EngL J. Med. (1982) 306(9):517–522.
   PubMed Web of Science ®Google Scholar
• •This is a classic article describing dramatic regression of refractory lymphoma after passive administration of anti-idiotypic monoclonal antibodies. This was the first description of successful monoclonal antibody therapy for human cancer.
   Google Scholar
• DAVE SS, WRIGHT G, TAN B et aL: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N EngL J. Med. (2004) 351(21):2159–2169.
   PubMed Web of Science ®Google Scholar
• LEVY R, WARNKE R, DORFMAN RF, HAIMOVICH J: The monoclonality of human B-cell lymphomas. J. Exp. Med. (1977) 145(4):1014–1028.
   PubMed Web of Science ®Google Scholar
• STEVENSON GT, STEVENSON FK: Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature (1975) 254(5502):714–716.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MJ, CARROLL W, KON S et al.: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. ImmunoL (1987) 139(8):2825–2833.
   Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK, HART S, MILLER RA, LEVY R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N EngL J. Med. (1992) 327(17):1209–1215.
   PubMed Web of Science ®Google Scholar
• •This is the first report of Id vaccination for human lymphoma.
   Google Scholar
• HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89(9):3129–3135.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates a strong association between the induction of an anti-Id immune response and favourable clinical outcome.
   Google Scholar
• ABE A, EMI N, TAJI H, KASAI M, KOHNO A, SAITO H: Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Gene Ther. (1996) 3(11):988–993.
   PubMed Web of Science ®Google Scholar
• CAO W, MYERS-POWELL BA, BRACIALE TJ: Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J. Exp. Med. (1994) 179(1):195–202.
   PubMed Web of Science ®Google Scholar
• OSTERROTH F, ALKAN o, MACKENSEN A et al.: Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. Immunol. Methods (1999) 229(1-2):141–153.
   PubMed Web of Science ®Google Scholar
• NELSON EL, LI X, HSU FJ et al.: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood (1996) 88(2):580–589.
   PubMed Web of Science ®Google Scholar
• CASPAR CB, LEVY S, LEVY R: Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood (1997) 90(9):3699–3706.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM: Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. Adv. PharmacoL (2004) 51:271–293.
   PubMedGoogle Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK, LILES TM, LEVY R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92(4):1184–1190.
   PubMed Web of Science ®Google Scholar
• GEORGE AJ, TUTT AL, STEVENSON FK: Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. immune/. (1987) 138(2):628–634.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM, LEVY R: Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. (2000) 164(9):4797–4803.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MJ, ESSERMAN L, BYARS NE, ALLISON AC, LEVY R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. (1990) 145(3):1029–1036.
   Google Scholar
• WENG WK, CZERWINSKI D, TIMMERMAN J, HSU FJ, LEVY R: Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Clin. OncoL (2004) 22(23):4717–4724.
   Web of Science ®Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99(3):754–758.
   PubMed Web of Science ®Google Scholar
• LUNDIN KU, HOFGAARD PO, OMHOLT H, MUNTHE LA, CORTHAY A, BOGEN B: Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 102(2):605–612.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG AC, DERMIME S, MULRYAN K, STERN PL, BHATTACHARYYA T, HAWKINS RE: Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. Immunother. (2004) 27(3):227–231.
   Web of Science ®Google Scholar
• LYNCH RG, GRAFF RJ, SIRISINHA S, SIMMS ES, EISEN HN: Myeloma proteins as tumor-specific transplantation antigens. Proc. NatL Acad. Sci. USA (1972) 69(6):1540–1544.
   PubMed Web of Science ®Google Scholar
• LEVY R, DILLEY J: Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc. Natl. Acad. Sci. USA (1978) 75(5):2411–2415.
   PubMed Web of Science ®Google Scholar
• MEEKER TC, LOWDER J, MALONEY DG et aL: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 65(6):1349–1363.
   PubMed Web of Science ®Google Scholar
• MEEKER T, LOWDER J, CLEARY ML et al.: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N EngL J. Med. (1985) 312(20:1658–1665.
   PubMedGoogle Scholar
• KAMINSKI MS, KITAMURA K, MALONEY DG, LEVY R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. (1987) 138(4):1289–1296.
   Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767–811.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM, LEVY R: Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. (1999) 50:507–529.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. (1996) 2(1):52–58.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM, CZERWINSKI DK, DAVIS TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99(5):1517–1526.
   PubMed Web of Science ®Google Scholar
• KWAK LW, YOUNG HA, PENNINGTON RW, WEEKS SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Nail. Acad. Sci. USA (1996) 93(20):10972–10977.
   PubMed Web of Science ®Google Scholar
• BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5(10):1171–1177.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated the ability ofId-ICLH plus GM-CSF vaccination to elicit tumour-specific immune responses and molecular CRs in follicular lymphoma. This established GM-CSF as a preferred adjuvant for Id-KLH vaccines.
   Google Scholar
• HAWKINS RE, ZHU D, OVECKA M et al.: Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood (1994) 83(11):3279–3288.
   Google Scholar
• TIMMERMAN JM, CZERWINSKI D, TAIDI B et al.: A Phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). Blood (2000) 96:Abstract #578.
   Google Scholar
• JONES I, MORIKAWA Baculovirus vectors for expression in insect cells. Curr. Opin. BiotechnoL (1996) 7(5):512–516.
   PubMed Web of Science ®Google Scholar
• ALTMANN F, STAUDACHER E, WILSON IB, MARZ L: Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj. J. (1999) 16(2):109–123.
   PubMed Web of Science ®Google Scholar
• ZHU D, MCCARTHY H, OTTENSMEIER CH, JOHNSON P, HAMBLIN TJ, STEVENSON FK: Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood (2002) 99(7):2562–2568.
   PubMed Web of Science ®Google Scholar
• REDFERN C, GUTHRIE TH, ADLER M et al.: Single agent activity of FavId [Id-KLH vaccine] for indolent NHL. Blood (2003) 102(11):Abstract #3341.
   Google Scholar
• •Paper of interest.
   Google Scholar
• QIN Z, RICHTER G, SCHULER T, IBE S, CAO X, BLANKENSTEIN T: B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. (1998) 4(5):627–630.
   PubMed Web of Science ®Google Scholar
• WILSON WH, ROSENWALD A. WHITE T et al.: Idiotype vaccine and dose-adjusted EPOCH-rituximab treatment in untreated mantle cell lymphoma: preliminary report on clinical outcome and analysis of immune response. Blood (2003) 102(11):Abstract #358.
   Google Scholar
• KOC ON, REDFERN C, WIERNIK PH et al.: Id/KLH vaccine (FavIdTm) following treatment with rituximab: an analysis of response Rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Blood (2004) 101(11):Abstract #587.
   Google Scholar
• •Paper of interest.
   Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20(10):2453–2463.
   PubMed Web of Science ®Google Scholar
• HOLMAN P, CORRINGHAM S, BASHEY A et ed.: Early and robust immune responses to idiotype (Id) Vaccination Occur In Mantle Cell Lymphoma (MCL) and indolent lymphoma (IL) patients 851 following autologous stem cell transplantation (ASCT). Blood (2003) 102(11):Abstract #3345.
   Google Scholar
• REDFERN C, SMITH MR, ADLER M et al.: A Phase II trial of FavidTm for relapsed indolent non-Hodgkin's lymphoma. Blood (2002) 100:Abstract #1383.
   Google Scholar
• VEELKEN H, MIKESCH K, OSTERROTH F et al.: Immune responses and clinical outcome of patients with advanced non-Hodgkins Lymphoma after immunization with a novel recombinant idiotype vaccine. Blood (2003) 102(11):Abstract #3342.
   Google Scholar
• BERTINETTI CM: Characterization of cellular immune responses to a recombinant idiotype vaccine by ELISPOT and identification of MHC class I-restricted T cell epitopes by peptide mapping. Blood (2004) 104(11):Abstract #1409.
   Google Scholar
• REDDY SA, RAJAPAKSA R, REINL S et al.: Plant derived single-chain Ey idiotype vaccines are safe and immunogenic in patients with follicular lymphoma: results of a Phase I study. Blood (2002):Abstract #609.
   Google Scholar
• KANTER G YJ, VOLOSHIN A, SWARTZ JR, LEVY R: A novel method for producing custom-made idiotype vaccines for lymphoma immunotherapy using a cell-free expression system. Blood (2004) 104(11):Abstract #1410.
   Google Scholar
• YANG J, KANTER G, VOLOSHIN A et al: Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng (2005) 89(5):503–511.
   PubMed Web of Science ®Google Scholar